An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: Opportunities and challenges in cancer therapy

Ying Qing Wang, Pingyuan Wang, Yu Ting Wang, Guang Fu Yang, Ao Zhang, Ze Hong Miao

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

Poly(ADP-ribose)polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug that selectively kills cancer cells by targeting homologous recombination repair defects. Since 2010, important advances have been achieved in PARP-1 inhibitors. Specifically, the approval of olaparib in 2014 for the treatment of ovarian cancer with BRCA mutations validated PARP-1 as an anticancer target and established its clinical importance in cancer therapy. Here, we provide an update on PARP-1 inhibitors, focusing on breakthroughs in their clinical applications and investigations into relevant mechanisms of action, biomarkers, and drug resistance. We also provide an update on the design strategies and the structural types of PARP-1 inhibitors. Opportunities and challenges in PARP-1 inhibitors for cancer therapy will be discussed based on the above advances.

Original languageEnglish (US)
Pages (from-to)9575-9598
Number of pages24
JournalJournal of Medicinal Chemistry
Volume59
Issue number21
DOIs
StatePublished - Nov 10 2016
Externally publishedYes

Fingerprint

Neoplasms
Therapeutics
DNA Repair Enzymes
Recombinational DNA Repair
Enzyme Inhibitors
Drug Resistance
DNA Repair
Ovarian Neoplasms
Poly (ADP-Ribose) Polymerase-1
Poly(ADP-ribose) Polymerase Inhibitors
Biomarkers
Mutation
Pharmaceutical Preparations
olaparib

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors : Opportunities and challenges in cancer therapy. / Wang, Ying Qing; Wang, Pingyuan; Wang, Yu Ting; Yang, Guang Fu; Zhang, Ao; Miao, Ze Hong.

In: Journal of Medicinal Chemistry, Vol. 59, No. 21, 10.11.2016, p. 9575-9598.

Research output: Contribution to journalReview article

Wang, Ying Qing ; Wang, Pingyuan ; Wang, Yu Ting ; Yang, Guang Fu ; Zhang, Ao ; Miao, Ze Hong. / An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors : Opportunities and challenges in cancer therapy. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 21. pp. 9575-9598.
@article{9940a96aa6e94193a93af4fdc74095c3,
title = "An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: Opportunities and challenges in cancer therapy",
abstract = "Poly(ADP-ribose)polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug that selectively kills cancer cells by targeting homologous recombination repair defects. Since 2010, important advances have been achieved in PARP-1 inhibitors. Specifically, the approval of olaparib in 2014 for the treatment of ovarian cancer with BRCA mutations validated PARP-1 as an anticancer target and established its clinical importance in cancer therapy. Here, we provide an update on PARP-1 inhibitors, focusing on breakthroughs in their clinical applications and investigations into relevant mechanisms of action, biomarkers, and drug resistance. We also provide an update on the design strategies and the structural types of PARP-1 inhibitors. Opportunities and challenges in PARP-1 inhibitors for cancer therapy will be discussed based on the above advances.",
author = "Wang, {Ying Qing} and Pingyuan Wang and Wang, {Yu Ting} and Yang, {Guang Fu} and Ao Zhang and Miao, {Ze Hong}",
year = "2016",
month = "11",
day = "10",
doi = "10.1021/acs.jmedchem.6b00055",
language = "English (US)",
volume = "59",
pages = "9575--9598",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "21",

}

TY - JOUR

T1 - An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors

T2 - Opportunities and challenges in cancer therapy

AU - Wang, Ying Qing

AU - Wang, Pingyuan

AU - Wang, Yu Ting

AU - Yang, Guang Fu

AU - Zhang, Ao

AU - Miao, Ze Hong

PY - 2016/11/10

Y1 - 2016/11/10

N2 - Poly(ADP-ribose)polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug that selectively kills cancer cells by targeting homologous recombination repair defects. Since 2010, important advances have been achieved in PARP-1 inhibitors. Specifically, the approval of olaparib in 2014 for the treatment of ovarian cancer with BRCA mutations validated PARP-1 as an anticancer target and established its clinical importance in cancer therapy. Here, we provide an update on PARP-1 inhibitors, focusing on breakthroughs in their clinical applications and investigations into relevant mechanisms of action, biomarkers, and drug resistance. We also provide an update on the design strategies and the structural types of PARP-1 inhibitors. Opportunities and challenges in PARP-1 inhibitors for cancer therapy will be discussed based on the above advances.

AB - Poly(ADP-ribose)polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug that selectively kills cancer cells by targeting homologous recombination repair defects. Since 2010, important advances have been achieved in PARP-1 inhibitors. Specifically, the approval of olaparib in 2014 for the treatment of ovarian cancer with BRCA mutations validated PARP-1 as an anticancer target and established its clinical importance in cancer therapy. Here, we provide an update on PARP-1 inhibitors, focusing on breakthroughs in their clinical applications and investigations into relevant mechanisms of action, biomarkers, and drug resistance. We also provide an update on the design strategies and the structural types of PARP-1 inhibitors. Opportunities and challenges in PARP-1 inhibitors for cancer therapy will be discussed based on the above advances.

UR - http://www.scopus.com/inward/record.url?scp=84994908887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994908887&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b00055

DO - 10.1021/acs.jmedchem.6b00055

M3 - Review article

C2 - 27416328

AN - SCOPUS:84994908887

VL - 59

SP - 9575

EP - 9598

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 21

ER -